期刊文献+

培美曲塞对晚期肺腺癌化疗及靶向治疗失败后的治疗效果分析 被引量:1

下载PDF
导出
摘要 目的分析晚期肺腺癌化疗及靶向治疗失败后应用培美曲塞治疗的效果。方法选取在我院接受诊治的56例晚期肺腺癌患者作为研究对象,依据系统抽样法将其分为参照组和研讨组,每组23例。两组均接受过化疗和靶向治疗,但均失败,参照组则给予给予支持治疗和对症治疗,研讨组则在参照组基础上给予培美曲塞进行治疗,对两组患者治疗效果进行分析。结果观察两组患者治疗3个月的临床疗效发现,研讨组总有效率高于参照组,P<0.05,两组间差异显著且具有统计学意义。观察两组患者治疗3、6及12个月的生存率发现,治疗3个月生存率无显著差异(P>0.05),治疗6个月及12个月后研讨组生存率均高于参照组(P<0.05),两组间差异显著且具有统计学意义。结论培美曲塞对晚期肺腺癌化疗及靶向治疗失败后的治疗效果显著,可对临床疗效提升,延缓患者生存期,值得在临床上推广应用。
出处 《内蒙古医学杂志》 2019年第2期209-210,共2页 Inner Mongolia Medical Journal
基金 河南省科技攻关计划项目(201602083)
  • 相关文献

二级参考文献60

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1571
  • 2游捷,施志明.肺癌国际生存质量量表与体能状态评定指标及中医症状量表的关系[J].中国中西医结合杂志,2005,25(7):595-599. 被引量:58
  • 3Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
  • 4Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer ( FASTACT-2 ) : a randomised, double-blind trial[J]. Lancet Oncol, 2013, 14(8) :777-786.
  • 5Zhang Y, Sun Y, Wang L, et al. Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase Ⅲ trials [ J ]. Oncol Targets Ther, 2013, 6 : 1771-1777.
  • 6Hattori Y, Satouchi M, Shimada T, et al. A phase 2 study of be- vacizumab in combination with carboplatin and paclitaxel in pa- tients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors ( HANSHIN On- cology Group 0109) [J]. Lung Cancer, 2015, 87(2) :136-140.
  • 7Dong L, Han ZF, Feng ZH, et al. Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall- cell lung cancer after the failure of epidermal growth factor recep- tor-tyrosine kinase inhibitors[ J]. J Int Med Res, 2014,42( 1 ) : 191-197.
  • 8Lee JC, Jang SH, Lee KY, et al. Treatment of non-small cell lung carcinoma after failure of epidermal growth factor receptor tyrosine kinase inhibitor[ J]. Cancer Res Treat, 2013, 45(2) : 79-85.
  • 9Iwasaki K, Osaka Y, Tachibana S, et al. Phase I Study of do- cetaxel, cisplatin, and 5-fluorouracil chemoradiotherapy for local or metastatic esophageal cancer [ J ]. Anticancer Res, 2016, 36 (3) :987-994.
  • 10Cai Y, Yah X, Zhang G, et al. MicroRNA-205 increases the sensitivity of docetaxel in breast cancer[J]. Oncol Lett, 2016, 11(2) :1105-1109.

共引文献60

同被引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部